Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration
Authors:
- Michael TagenMTMichael Tagen
- Stacy ThromSTStacy Throm
- Jeremy MallariJMJeremy Mallari
- Laura MillerLMLaura Miller
- R. Kiplin GuyRGR. Kiplin Guy
- Michael A. DyerMDMichael A. Dyer
- Richard T. WilliamsRWRichard T. Williams
- Martine F. RousselMRMartine F. Roussel
- Katie NemethKNKatie Nemeth
- Fangyi ZhuFZFangyi Zhu
- Jiakun ZhangJZJiakun Zhang
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (1) , 15-21
Abstract
Nutlin-3a is an MDM2 inhibitor that is under investigation in preclinical models for a variety of pediatric malignancies, including retinoblastoma, rhabdomyosarcoma, neuroblastoma, and leukemia. We used physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of nutlin-3a in the mouse. Plasma protein binding and blood partitioning were assessed by in vitro studies. After intravenous (10 and 20 mg/kg) and oral (50, 100, and 200 mg/kg) dosing, tissue concentrations of nutlin-3a were determined in plasma, liver, spleen, intestine, muscle, lung, adipose, bone marrow, adrenal gland, brain, retina, and vitreous fluid. The PBPK model was simultaneously fit to all pharmacokinetic data using NONMEM. Nutlin-3a exhibited nonlinear binding to murine plasma proteins, with the unbound fraction ranging from 0.7 to 11.8%. Nutlin-3a disposition was characterized by rapid absorption with peak plasma concentrations at approximately 2 h and biphasic elimination consistent with a saturable clearance process. The final PBPK model successfully described the plasma and tissue disposition of nutlin-3a. Simulations suggested high bioavailability, rapid attainment of steady state, and little accumulation when administered once or twice daily at dosages up to 400 mg/kg. The final model was used to perform simulations of unbound tissue concentrations to determine which dosing regimens are appropriate for preclinical models of several pediatric malignancies.Keywords
This publication has 36 references indexed in Scilit:
- Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS)Journal of Pharmaceutical and Biomedical Analysis, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53JNCI: Journal of the National Cancer Institute, 2009
- Targeting the p53–MDM2 interaction to treat cancerBritish Journal of Cancer, 2004
- Protein levels in the vitreous of rats with streptozotocin-induced diabetes mellitusBrain Research Bulletin, 1993
- Absence of p53 gene mutations in primary neuroblastomas.1993
- Nonlinear protein binding and enzyme heterogeneity: Effects on hepatic drug removalJournal of Pharmacokinetics and Biopharmaceutics, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- p53 Mutations in Human CancersScience, 1991
- Vitreous seeds in retinoblastoma, clinical significance and ultrastructureGraefe's Archive for Clinical and Experimental Ophthalmology, 1979